Cytokinetics Inc vs iShares Core High Dividend ETF — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while iShares Core High Dividend ETF trades at $27.6. Which is the better fit depends on your goals.
| CYTK | HDV | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | — |
52-Week High | $87.26 | $28.09 |
52-Week Low | $33.23 | $23.63 |
Enterprise Value | $11.59B | — |
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
HDV (iShares Core High Dividend ETF) trades at $27.93, up 0.83% with a bullish technical signal from moving averages. The ETF focuses on high-quality U.S. dividend stocks with a 3.0% yield, emphasizing defensive sectors like healthcare and energy. Recent performance shows strong total returns with lower volatility than the S&P 500, supported by a 1:5 stock split executed in April 2026.
HDV offers attractive income generation with quality screening, though its concentrated energy exposure (21.56%) introduces sector-specific volatility. The ETF's low expense ratio and defensive positioning provide stability, but investors should monitor oil price sensitivity. Long-term dividend growth potential remains favorable amid current market conditions.
Trailing returns across standard periods
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →